SAM
PLRX icon

Smartleaf Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Smartleaf Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,975
Closed -$4.37K – 2913
2025
Q1 		$4.37K Buy
2,975
+2,200
+284% +$13.4K ﹤0.01% 2236
2024
Q4 		$9.91K Buy
775
+542
+233% +$7.4K ﹤0.01% 1987
2024
Q3 		$2.63K Buy
233
+135
+138% +$1.69K ﹤0.01% 2392
2024
Q2 		$1.04K Buy
+98
New +$1.26K ﹤0.01% 2410

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Smartleaf Asset Management's PLRX Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 2,975 shares — an estimated $4.37K sold.

Smartleaf Asset Management first reported a position in PLRX in Q2 2024 and held it in 4 quarters. The position peaked at $9.91K in Q4 2024. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 2,975 Pliant Therapeutics shares in Q2 2025, an estimated $4.37K.
  • Smartleaf Asset Management first reported a position in Pliant Therapeutics in Q2 2024 and held it in 4 quarters.
  • Smartleaf Asset Management's Pliant Therapeutics position peaked at $9.91K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.